Therapix Biosciences Ltd.
TRPX
TRPX was delisted on the 1st of July, 2020.
4 hedge funds and large institutions have $333K invested in Therapix Biosciences Ltd. in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 5 closing their positions.
57% more capital invested
Capital invested by funds: $212K → $333K (+$121K)
33% less funds holding
Funds holding: 6 → 4 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$163K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$128K |
| 3 |
APA
American Portfolios Advisors
Holbrook,
New York
|
+$813 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$58.6K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$35K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$15K |
| 4 |
Barclays
London,
United Kingdom
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Hudson Bay Capital Management
Stamford,
Connecticut
| $125K | +$163K | +40,055 | New |
|
|
2
Morgan Stanley
New York
| $109K | -$58.6K | -14,422 | -29% |
|
|
CH
3
CVI Holdings
Wilmington,
Delaware
| $98K | +$128K | +31,397 | New |
|
|
APA
4
American Portfolios Advisors
Holbrook,
New York
| $626 | +$813 | +200 | New |
|
|
OAM
5
Oxford Asset Management
Oxford,
United Kingdom
| – | -$35K | -10,709 | Closed |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$15K | -4,612 | Closed |
|
|
7
Barclays
London,
United Kingdom
| – | -$2K | -681 | Closed |
|
TRPX Hedge Fund Activity: Q1 2019 in Review
4 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Therapix Biosciences Ltd. (TRPX) for Q1 2019, worth a combined $333K — up 57% from $212K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TRPX and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $163K. The largest seller was Morgan Stanley, cutting an estimated $58.6K.
- 4 institutional investors held Therapix Biosciences Ltd. (TRPX) as of Q1 2019, down from 6 in Q4 2018.
- Funds reported $333K of Therapix Biosciences Ltd. stock for Q1 2019, up 57% quarter-over-quarter.
- 3 funds opened new Therapix Biosciences Ltd. positions in Q1 2019 and 5 closed out, a net change of -2 holders.
- The largest Therapix Biosciences Ltd. buyer in Q1 2019 was Hudson Bay Capital Management, an estimated $163K added.
- The largest Therapix Biosciences Ltd. seller in Q1 2019 was Morgan Stanley, an estimated $58.6K sold.
Based on aggregated 13F filings for Q1 2019.